MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
February 14, 2022 16:01 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
September 16, 2021 02:45 ET | MacroGenics, Inc.
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
September 12, 2021 19:00 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
July 29, 2021 16:01 ET | MacroGenics, Inc.
Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) MeetingConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md.,...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
February 11, 2021 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces MGD019 Publication in Cell Reports Medicine
December 22, 2020 11:35 ET | MacroGenics, Inc.
ROCKVILLE, MD, Dec. 22, 2020 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
December 15, 2020 08:05 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
November 30, 2020 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
provectus_logo.jpg
Provectus Receives Notice of Allowance for Fourth Cancer Combination Therapy Patent from the United States Patent and Trademark Office
July 15, 2019 08:00 ET | Provectus Biopharmaceuticals Inc.
- Further patent protection of combinations of intratumoral PV-10 and checkpoint inhibitor (CI) drugs for the treatment of multiple, different, solid tumor cancers KNOXVILLE, TN, July 15, 2019 ...
Biodesix_lockup_r_rgb (2).jpg
Biodesix Test Predicts Response to Atezolizumab in Lung Cancer
November 12, 2018 09:00 ET | Biodesix, Inc.
Researchers Present New Data from Blood-Based Proteomic Test in Biomarkers and Immune Monitoring at SITC 2018   BOULDER, Colo. and WASHINGTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Researchers with...